PioneerUniverse8
3 days ago
Nothing that we didn't know, but still pretty impressive since it took less than 5 minutes:
Sources of Recurring Revenue: Enanta’s primary recurring revenue comes from royalties on AbbVie’s hepatitis C virus (HCV) drug MAVYRET®/MAVIRET® (a combination of glecaprevir/pibrentasvir). Enanta co-discovered the protease inhibitor glecaprevir, and under its agreement with AbbVie it earns tiered double-digit royalties on 50% of net sales of the MAVYRET/MAVIRET regimen?
IN.MARKETSCREENER.COM
. In fiscal 2023, Enanta earned about $79–$86 million in royalty revenue from AbbVie’s MAVYRET sales?
SEC.GOV
, which made up essentially all of the company’s revenue. This royalty stream has been ongoing since MAVYRET’s 2017 launch and remains a leading HCV therapy, though sales have been declining modestly year over year as the pool of untreated HCV patients shrinks?
SEC.GOV
. Enanta does not currently have other significant recurring revenues (no marketed proprietary drugs of its own), aside from minor interest income on its cash holdings (for example, ~$3–5 million per quarter in interest income recently?
IR.ENANTA.COM
).Partial Royalty Monetization: In April 2023, Enanta sold 54.5% of its future MAVYRET royalties (from July 2023 through June 2032) to the Canadian pension plan OMERS for a $200 million upfront payment?
BUSINESSWIRE.COM
. Enanta retains the remaining 45.5% of those royalties during that period, after which 100% of royalties will revert to Enanta (or earlier if a 1.42× payment cap is reached)?
BUSINESSWIRE.COM
. For accounting purposes, Enanta still reports 100% of the royalties as revenue and treats the OMERS payment as a liability (amortized as royalties are paid out to OMERS)?
SEC.GOV
. The royalty sale was a non-dilutive way to bolster cash for R&D, but it reduces the portion of future royalty cash flows that Enanta will directly receive.Royalty Stream NPV: We can estimate the net present value (NPV) of Enanta’s retained royalty stream. AbbVie’s MAVYRET sales have been trending downward (e.g. Enanta’s FY2023 royalties of ~$79M were down from ~$86M in FY2022 due to lower HCV sales?
IR.ENANTA.COM
). Assuming a continued decline (for instance, on the order of ~10% per year as the HCV patient pool contracts), the annual royalties attributable to Enanta’s remaining 45.5% stake might fall from roughly ~$35–40 million (Enanta’s share) in the near term to perhaps ~$15–20 million by 2031. Using a 10–12% discount rate, the NPV of Enanta’s retained royalty portion through 2032 can be estimated on the order of $130–$150 million. For example, under a scenario of royalties declining ~10% annually from an ~$79M base (100% royalty in FY2023) and using a 10% discount rate, Enanta’s 45.5% share yields roughly $140 million NPV (this aligns with the OMERS deal implying a total stream value in the mid-$300M range for 100% of royalties).Calculation detail: Enanta received $200M for a 54.5% share of royalties capped at $284M?
BUSINESSWIRE.COM
. This suggests the full stream was valued in the ballpark of $366M (uncapped) on a risk-adjusted basis. Enanta’s remaining share plus any post-2032 tail could thus be worth roughly $166M (uncapped) by the same measure. After discounting to present value (and given the cap risk), our ~$130–150M NPV estimate for Enanta’s portion is reasonable. In summary, Enanta’s recurrent royalty revenue – primarily from MAVYRET – has a substantial, measurable value on a DCF basis (well into nine figures) even as the HCV franchise gradually declines.
Financial Position & Cash Burn
Cash and Investments: Enanta’s balance sheet is strong, with a large cash reserve from past royalties and the OMERS monetization. As of September 30, 2023 (end of FY2023), Enanta had $370 million in cash, equivalents and marketable securities?
SEC.GOV
?
SEC.GOV
. By September 30, 2024, cash had declined to about $248.2 million?
IR.ENANTA.COM
, reflecting the year’s operational spending. Most recently, at December 31, 2024, cash stood at $216.7 million?
IR.ENANTA.COM
. Enanta carries no traditional debt – the only significant liability is the accounting “royalty financing” liability corresponding to the OMERS deal (the $200M upfront is recorded as a debt-like liability to be paid down via the 54.5% royalty pass-through)?
SEC.GOV
. Aside from that, Enanta’s other liabilities (accounts payable, lease obligations, etc.) are relatively minor compared to its cash hoard.Cash Burn Rate: Enanta has been operating at a substantial net loss due to heavy R&D investment. In FY2023, the net loss was $133.8 million (loss of $6.38 per share)?
SEC.GOV
, slightly higher than the $121.8M loss in FY2022. R&D expense in FY2023 was $163.5M, with an additional ~$52M in G&A?
SEC.GOV
. The company recognized $79M in revenue that year from royalties?
SEC.GOV
, so operating cash burn (excluding the one-time royalty sale) was on the order of $120–130M for the year. In FY2024, Enanta moved to reduce spending: management guided R&D expense down to $100–120M and G&A to $45–50M?
SEC.GOV
. This represents a meaningful cut (>25%) in R&D outlays to slow the burn. Indeed, Enanta’s quarterly net losses have started to shrink (e.g. $22.3M loss in a recent quarter versus $33.4M in the prior year’s quarter?
QZ.COM
), indicating cost controls.At the FY2024 spending pace (~$145–170M/year operating costs) and assuming royalty and interest income on the order of ~$70–80M/year, Enanta’s net cash burn is roughly ~$70–90 million per year. The company explicitly states that its existing cash plus ongoing royalty inflows are sufficient to fund operations through fiscal 2027?
SEC.GOV
. This projected runway suggests that, barring major changes, Enanta has about 3+ years of funding for its R&D programs before needing additional capital. The net cash position (cash minus any debt) is effectively ~$216M as of end-2024 (or ~$10 per share in cash, after accounting for a few quarters of burn). Even including the $200M royalty liability as debt, the net cash would still be roughly equal to the remaining cash because that liability is serviced by future royalties rather than by drawing down cash reserves.Liabilities: Other than the royalty obligation, Enanta’s balance sheet shows minimal debt. The OMERS royalty liability was initially $200M and will decline as royalties are paid out?
SEC.GOV
. Importantly, this is non-recourse to Enanta’s other assets (OMERS recoups only from MAVYRET royalties, capped at $284M)?
BUSINESSWIRE.COM
. Enanta’s accounts payable and accrued expenses are relatively low (for instance, R&D and trial costs accrued each quarter, but these are part of operating expenses). There are no indications of significant hidden liabilities that could jeopardize the cash position. Therefore, Enanta’s financial position is very liquid and solvent, with its cash vastly exceeding any obligations. The key question is how effectively that cash will be used to create value (through successful R&D) versus consumed by ongoing losses.
Stock Valuation & Comparison
Market Cap vs Cash and Assets: Enanta’s current market valuation appears exceptionally low relative to its assets. At recent prices around $5–6 per share (early 2025), Enanta’s market capitalization is only about $100–120 million?
MACROTRENDS.NET
?
MACROTRENDS.NET
. This is far below the company’s cash holdings alone – for example, cash was ~$248M at FY2024 and ~$216M at the end of 2024, which equates to ~$11.70 per share in cash?
REUTERS.COM
. In other words, the stock trades at roughly half of its cash book value, implying a deeply negative enterprise value once one subtracts net cash. Even adding the NPV of the remaining royalty stream (estimated ~$130M+) to the cash, Enanta’s asset coverage is several times the market cap. The market is effectively assigning little or no value (or even negative value) to Enanta’s drug pipeline – it values the company at less than cash-on-hand, suggesting investors believe a significant portion of that cash will be burned without yielding returns.To put this in context, Enanta’s enterprise value (EV) is negative. With ~$216M cash and a ~$110M market cap, EV is roughly –$100 million (i.e. the market cap minus cash). This indicates extreme pessimism. By comparison, many development-stage biotech peers trade near or above 1× cash if their pipelines have promise. Enanta’s discount to cash is unusually steep even in a generally beaten-down biotech sector. The stock’s price-to-book ratio is well below 1 (signaling investors doubt the book assets will translate into shareholder value). Furthermore, Enanta’s price-to-sales ratio is also low given ~$68–79M annual royalty revenue?
MACROTRENDS.NET
; the market cap is barely 1.3× trailing royalty revenue – very low for a biotech with a revenue stream.Historical Stock Performance: Enanta’s stock has declined dramatically from prior highs. It reached an all-time high of ~$126/share in 2018 when HCV royalties were robust and investor optimism about its pipeline (and HCV franchise) was high?
MACROTRENDS.NET
?
MACROTRENDS.NET
. Even in recent years, the stock traded in the $50–70 range in 2021–2022?
MACROTRENDS.NET
. However, a combination of factors (discussed below) caused a slide to the mid-teens in 2023 and then a collapse to single digits in 2024, hitting a 52-week low of $4.71?
MACROTRENDS.NET
. Currently, at ~$5–6, the stock is at multi-year lows not seen since 2017. Relative to peers, Enanta’s valuation appears anomalously low: many biotech companies with a single late-stage asset and no revenue might trade at >$200M market caps, whereas Enanta has a steady royalty income and multiple pipeline programs yet is valued barely above $100M. This suggests that the market is extremely skeptical about Enanta’s ability to generate future value from its pipeline or even to fully capitalize on its cash (perhaps expecting the cash to be eroded by ongoing losses).Peer Comparison: In the antiviral development space, Enanta could be compared to other small-cap biotechs with royalty income or those developing RSV or hepatitis treatments. While direct apples-to-apples peers are few, one can note that Enanta’s price-to-cash ratio is far lower than most. Investors appear to be pricing Enanta as if its pipeline is worth less than zero, which is a stance typically reserved for companies facing imminent distress or major pipeline failures. The broader biotech bear market has driven many stocks below cash value, but Enanta’s case stands out because it does have a revenue-generating asset and a track record of successful drug discovery (MAVYRET’s development). This discrepancy underscores a potentially significant valuation disconnect – either the market is overly penalizing Enanta for risks, or there are serious concerns about future prospects (or a bit of both).
Potential Risks & Market Perception
The deep discounted valuation of Enanta reflects multiple risks and negative market perceptions:
Declining HCV Royalties: Enanta’s sole revenue source is shrinking. The HCV market is mature – many patients have been cured, and fewer new patients require treatment each year. AbbVie’s MAVYRET sales have been trending down (e.g. ~8–10% decline in 2023 vs 2022)?
SEC.GOV
. While MAVYRET remains a leading therapy, the continued slide in royalty revenue is a concern. The royalty stream is finite (the OMERS deal effectively “ends” Enanta’s full participation by 2032), and there is a possibility that sales could fall faster due to competition or eventual generic entrants. This means Enanta’s recurrent revenue base will likely dwindle over time, putting more pressure on the pipeline to deliver new revenue sources.
Heavy Cash Burn and No Profitable Products: Enanta is still a clinical-stage biotech beyond the HCV royalties. Its R&D programs (for RSV, hepatitis B, human metapneumovirus, etc.) consume a lot of cash, and none are yet approved or generating revenue. The company has been losing over $100M per year?
SEC.GOV
, essentially using its royalty income and cash reserves to fund trials. Investors worry that Enanta could burn through its cash by 2027 (when current cash is projected to run out?
SEC.GOV
) without producing a successful drug. If that happens, Enanta might need dilutive equity raises or other financings. This risk of “cash burn without payoff” leads the market to heavily discount the company’s cash – every $1 in cash is valued at much less, since it may be spent on unsuccessful R&D.
Pipeline Uncertainty and R&D Risk: Enanta’s pipeline is focused on antiviral programs that carry significant technical and regulatory risk. Notably, its lead internal program in respiratory syncytial virus (RSV), the N-protein inhibitor EDP-938 (generic name zelicapavir), has encountered setbacks. In May 2022, a Phase 2b trial of EDP-938 in otherwise healthy adult RSV patients failed to meet its primary endpoint, causing the stock to plunge to its lowest level since 2017?
CAFEPHARMA.COM
. More recently, Enanta was testing EDP-938 in higher-risk patient populations (pediatric and transplant patients). However, expectations have been tempered – the market has low confidence after the earlier failure. This was reinforced when top-line results in a Phase 2b RSV trial (likely in a low-risk population) reportedly “flamed out,” again sending the stock to multi-year lows?
CAFEPHARMA.COM
. Such trial failures highlight the real possibility that key programs might never reach approval. In addition, Enanta had a COVID-19 oral protease inhibitor (EDP-235) that was discontinued after Phase 1 due to liver enzyme elevations – another pipeline setback (and competition from approved drugs like Paxlovid made that program less viable). Overall, the pipeline has promise but has not yet produced a new winner, and clinical development is inherently fraught with risk of failure or delays (RSV trials, for example, can be affected by virus seasonality, trial recruitment challenges, etc.).
Competitive Pressures: In each of Enanta’s target areas, competition is intense. For RSV, big players like Pfizer and GSK have recently launched RSV vaccines for adults, and others (Johnson & Johnson via its ReViral acquisition, ReViral’s sisunatovir, etc.) are developing small-molecule RSV antivirals. Enanta’s RSV N-inhibitor must prove distinct value in high-risk patients to carve out a niche. There is also the threat that alternative approaches (e.g. long-acting monoclonal antibodies for infants, like nirsevimab, or other mechanism antivirals) could reduce the opportunity. In hepatitis B (HBV) and other virology targets Enanta is exploring, numerous biotech and pharma companies are competing, many of which may have more advanced candidates. This competitive landscape raises concern that even if Enanta’s R&D succeeds scientifically, the commercial opportunity might be limited or crowded, affecting the potential payoff.
Regulatory and Development Hurdles: Enanta’s drug candidates must navigate clinical trials and regulatory approval – processes that are lengthy and uncertain. For instance, Phase 3 trials would be needed for RSV candidates if Phase 2 results (in high-risk patients) are positive. Those trials would be expensive and time-consuming, likely pushing potential approval to 2026–2027 or beyond. Any regulatory setbacks, clinical holds, or safety issues could derail these programs. The market may be factoring in that even in a best-case scenario, Enanta is years away from a new product on the market, during which time a lot of cash will be spent. There is also some legal/regulatory risk in the form of a patent infringement lawsuit Enanta has initiated (as noted by their increased legal expenses?
SEC.GOV
) – while details aren’t provided in the question, such lawsuits (perhaps related to competitor drugs overlapping Enanta’s IP) can be costly and their outcomes uncertain.
Investor Sentiment and Recent Developments: The sentiment around Enanta has been quite bearish, reflecting both company-specific events and broader market trends. The biotech sector experienced a downturn in 2022–2023, and Enanta’s setbacks made it worse. Analysts have noted that Enanta’s share price decline appears disproportionate, possibly due to “the broader downturn in biotech, mixed results from their RSV treatment (zelicapavir), and possibly misplaced safety concerns”?
MARKETS.BUSINESSINSIDER.COM
. Essentially, bad news has piled on: the 2022 RSV trial failure, the high cash burn, and no major positive catalysts in 2023 led many investors to capitulate. By late 2024, as the stock hit all-time lows, some analysts suggested the market was not recognizing Enanta’s potential in its pipeline?
MARKETS.BUSINESSINSIDER.COM
and was “giving little credit” to anything beyond the cash and royalty projections?
MARKETS.BUSINESSINSIDER.COM
. Indeed, one JMP Securities analyst commented that Enanta’s valuation “appears to be limited to its current cash projections and retained economics from Mavyret, with little credit given to its broader pipeline.”?
MARKETS.BUSINESSINSIDER.COM
This lack of confidence can become a self-fulfilling prophecy in the short term, as a depressed stock makes financing harder and can pressure the company’s strategy.
It’s worth highlighting some recent positive developments that could counterbalance the risks, though the market’s reaction has been muted so far. In late 2024, Enanta announced positive Phase 2a results for EDP-323, an RSV L-protein inhibitor, in a human challenge study – demonstrating antiviral activity in healthy adults inoculated with RSV?
IR.ENANTA.COM
. Also, in September 2024 Enanta reported encouraging data from a pediatric RSV trial of EDP-938 (zelicapavir). In hospitalized and non-hospitalized infants (28 days to 36 months old), zelicapavir was well-tolerated and achieved target drug exposure; the company stated that “Zelicapavir demonstrated an antiviral effect on both primary endpoints, as well as secondary virology endpoints,” reinforcing its potential in high-risk settings?
CLINICALTRIALSARENA.COM
?
CLINICALTRIALSARENA.COM
. These developments suggest the pipeline still has life – particularly in RSV – but investors may be taking a “wait and see” approach until these translate into clear efficacy in Phase 2b/3 trials. In the meantime, the overhang of past trial failures and ongoing cash burn continues to dampen enthusiasm.In summary, the market’s deeply discounted valuation of Enanta can be explained by fears that the declining HCV royalties and large cash reserve will be exhausted by R&D efforts that might not succeed. Essentially, investors are pricing in a strong possibility that Enanta’s pipeline could fail to generate significant future revenue, leaving the company’s cash as the only asset – and even that cash will shrink over time with the current burn rate. This pessimistic view has been exacerbated by recent trial disappointments and a tough biotech funding climate. Only tangible signs of pipeline success or other value-creating events (partnerships, asset sales, etc.) are likely to change this perception.
Conclusion & Fair Value Outlook
Is Enanta underpriced? Based on the fundamentals, Enanta appears significantly underpriced relative to its liquid assets and royalty stream. The stock is trading at a deep discount to net cash – for example, ~$5–6 share price vs ~$11+ per share in cash?
REUTERS.COM
– which implies that the market expects substantial value destruction from here. However, if one assumes even a baseline scenario (no pipeline success but orderly use of cash), the intrinsic value would seem higher than the current price. Enanta’s net cash ($216M as of end-2024) plus the NPV of its retained royalties (~$130M) sum to roughly $350M, which on ~21 million shares would be about $16–$17 per share. In a sense, that $16–$17 could be viewed as a liquidation or floor value if the company simply ran down its HCV royalties and cash. The stock trading around one-third of that value suggests an overly bearish stance – or at least a very high risk discount being applied.Fair Value Estimate: A reasonable fair value for Enanta’s stock depends on how one weighs the pipeline prospects. If one were to assign zero value to the pipeline (assuming all pipeline programs fail), a fair value might roughly equal the net cash + royalty value indicated above (mid-teens per share, albeit declining over time as cash is spent). If one is more optimistic and assigns some probability-weighted value to the pipeline (for example, factoring in that at least one of the RSV programs could succeed and generate future cash flows), the fair value would be higher. Wall Street analysts with bullish views have set price targets around $20–$21 per share?
MARKETS.BUSINESSINSIDER.COM
?
MARKETS.BUSINESSINSIDER.COM
, which implicitly assume that Enanta will deliver on some pipeline milestones (e.g. successful Phase 2 results in RSV and advancement toward Phase 3) and that the market will start to credit those opportunities. Evercore ISI and JMP Securities both recently reiterated Buy ratings in Dec 2024, with targets near $20, seeing the sell-off as overdone?
MARKETS.BUSINESSINSIDER.COM
?
MARKETS.BUSINESSINSIDER.COM
.That said, for Enanta to realize a fair value closer to its intrinsic worth, it will likely need to demonstrate progress (or secure partnerships) in its pipeline in the coming 1-2 years. Successful trial readouts in RSV – for instance, showing clear efficacy in a high-risk population – could be a catalyst to change investor sentiment. Enanta’s management has a strong track record (they discovered a blockbuster HCV drug), and they are now deploying that expertise in new areas. If investors begin to view at least one of Enanta’s programs (RSV N-inhibitor, RSV L-inhibitor, HBV, etc.) as likely to succeed, the current discount to cash should narrow quickly. Conversely, the risks remain that continued cash burn and any further trial disappointments could keep the stock depressed.In conclusion, Enanta’s stock does appear undervalued on an asset basis, but the discount reflects real uncertainties. A fair value in the mid-teens per share can be justified by existing assets alone (cash + royalties), suggesting the current price is overly punitive. For long-term value, one must consider the pipeline: if Enanta’s RSV drugs or other candidates pan out, the upside could far exceed the mid-teens (given the multi-billion-dollar markets at stake). However, without pipeline success, that cash will dwindle. Investors seem to be taking a “prove it” attitude – essentially valuing Enanta at liquidation levels and waiting for clear evidence of a turnaround. Thus, for an investor who believes in Enanta’s science, the stock looks unduly cheap, whereas skeptics would argue the price is justified by the probability of cash burn. On balance, given the data we have, Enanta appears to be undervalued relative to its probable future value, with a reasonable fair value estimate around $15–$20 per share in the near-to-medium term (assuming no further negative surprises and some pipeline progress). This represents a significant premium over the current market price, suggesting a potential opportunity – albeit one accompanied by the high risk typical of biotech investments.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
DewDiligence
2 days ago
biotech_researcher
2 days ago
Hot Features
Premium
